Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study
NCT03870828 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 210
Last updated 2019-03-12
Summary
Interstitial pneumonia with autoimmune features (IPAF) was defined in 2015 by the Working Group of the European Respiratory Society (ERS) and the American Thoracic Society (ATS) as interstitial pneumonia with some clinical and/or serological features suggesting presence of an underlying autoimmune disorder. However, ofiicial criteria for diagnosis of an autoimmune disease are not met.
Aims of the study:
1. Determine the incindence of IPAF in comparison with interstitial lung diseases (ILDs) and classic autoimmune diseases (ADs) in polish pulmonological centers.
2. Clinical, serological, functional and radiological and histopathological characteristics of IPAF patients.
3. Analysis of diagnostic strategies towards specific IPAF subgroups.
4. Characterictics of potencial diagnostic, predictive and prognostic features of IPAF.
5. Prospective assessment of IPAF patients in the courseof 5 years in order to determine stability of the diagnosis and potential progression to other diseases, e.g. ADs.
Conditions
- Interstitial Lung Disease
- Interstitial Pneumonia
- Interstitial Fibrosis
- Autoimmune Diseases
Interventions
- DIAGNOSTIC_TEST
-
Bronchoalveolar lavage and taking bronchial mucosa samples
Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units. Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved.
- DIAGNOSTIC_TEST
-
6minute walk test
a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
- DIAGNOSTIC_TEST
-
Arterial blood gas
If SpO2 is measured to be \< 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
- PROCEDURE
-
Blood drawing
A vein will be punctured in order to take a blood sample for further tests
Sponsors & Collaborators
-
Medical University of Silesia
lead OTHER
Principal Investigators
-
Szymon Skoczynski, MD, PhD · Slaski Uniwersytet Medyczny
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-18
- Primary Completion
- 2020-02-18
- Completion
- 2025-12-31
Countries
- Italy
- Poland
Study Locations
More Related Trials
-
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
NCT00470327 ·Status: RECRUITING
-
An In Silico Trial to Evaluate Prospectively the Performance of a Radiomics Algorithm for UIP Compared to Medical Doctors
NCT05784207 ·Status: COMPLETED
-
A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease
NCT05492994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Idiopathic Pulmonary Fibrosis Job Exposures Study
NCT03211507 ·Status: COMPLETED
-
Evaluating the Diagnostic Performance of (HRCT) in IPD Fibrosis in Suspected Cases
NCT07048652 ·Status: ACTIVE_NOT_RECRUITING
-
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
NCT01915511 ·Status: RECRUITING
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
NCT04362644 ·Status: RECRUITING ·Phase: PHASE1
-
IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
NCT02803580 ·Status: COMPLETED
-
Study of the Etiology and Immunological Pathogenesis in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)
NCT02509364 ·Status: UNKNOWN
-
Investigating Idiopathic Pulmonary Fibrosis in Greece
NCT03074149 ·Status: COMPLETED
-
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
NCT05895409 ·Status: RECRUITING
-
Database for Interstitial Lung Disease
NCT04707781 ·Status: RECRUITING
-
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00373841 ·Status: RECRUITING
-
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
NCT02315586 ·Status: COMPLETED
-
Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases
NCT00005317 ·Status: COMPLETED
-
Families-At-risk for Interstitial Lung Disease Study
NCT03641742 ·Status: COMPLETED
-
Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study
NCT03836417 ·Status: COMPLETED
-
Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00258544 ·Status: ACTIVE_NOT_RECRUITING
-
Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis
NCT05988437 ·Status: NOT_YET_RECRUITING
-
Individual Sensitivity for Interstitial Lung Diseases
NCT00741572 ·Status: COMPLETED
-
A Prospective, Cohort Study of Hyperpolarized 3He MRI in Chronic Obstructive Pulmonary Disease
NCT02734368 ·Status: TERMINATED
-
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT02058602 ·Status: COMPLETED ·Phase: PHASE1
-
Case-Control Study of Fibrotic Interstitial Lung Disease (ILD) and Cardiac Disease / Interventions.
NCT01154998 ·Status: UNKNOWN
-
Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry
NCT00212511 ·Status: WITHDRAWN
-
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
NCT02594059 ·Status: COMPLETED ·Phase: NA